Monthly Archives: May 2017

Sanofi Pays ImmunoGen $30 Million in an Amended License Agreement

By | May 31, 2017

ImmunGen, which develops antibody-drug conjugates (ADCs) for the treatment of cancer, announced that it has amended its license agreements with Sanofi covering all compounds in development by Sanofi using ImmunoGen’s technology. Under the terms of the amended 2003 collaboration and license agreement, ImmunoGen has granted Sanofi a fully-paid, exclusive license to develop, manufacture, and commercialize… Read More »

Pfizer’s Epogen/Procrit Biosimilar gets FDA Advisory committee green light

By | May 26, 2017

Pfizer announced the FDA Oncologic Drugs Advisory Committee recommended approval of the Company’s proposed Epogen (Amgen) / Procrit (Johnson and Johnson) biosimilar across all indications. This is the first epoetin alfa biosimilar that has been recommended for approval by a U.S. FDA Advisory Committee. The product indications include treatment of anemia due to Chronic Kidney… Read More »

Sanofi and Regeneron Win FDA Approval of Kevzara for Rheumatoid Arthritis

By | May 25, 2017

“Today’s approval…not only underscores our ongoing commitment to making a difference in the lives of patients, but also demonstrates our drive to accelerate science and medicine in immunology.” So said Sanofi Chief Executive Officer Olivier Brandicourt as Sanofi and Regeneron Pharmaceuticals announced FDA approval of Kevzara® (sarilumab) for the treatment of adults with moderate to… Read More »

Thermo Fisher Scientific to Acquire CMO Patheon

By | May 18, 2017

The boards of directors at Thermo Fisher Scientific and Patheon have approved Thermo Fisher’s acquisition of Patheon for $35.00 per share in cash. The transaction represents a purchase price of approximately $7.2 billion, which includes the assumption of approximately $2.0 billion of net debt. Patheon provides contract development and manufacturing services, primarily at facilities in… Read More »

First New Treatment for ALS in More Than 20 Years Approved by FDA

By | May 11, 2017

MT Pharma America announced that the FDA has granted approval of Radicava (edaravone) to treat amyotrophic lateral sclerosis (ALS). ALS is a rapidly progressive neurodegenerative disease – the majority of patients die within two to five years of diagnosis. An estimated 6,000 Americans are diagnosed each year with ALS, an incurable disease that affects the… Read More »

Magenta Therapeutics Adds $50 Million for Stem Cell Development

By | May 11, 2017

Cambridge-based Magenta Therapeutics, a biotech company developing therapies to improve and expand the use of curative stem cell transplantation, has announced completion of a $50 million Series B financing; in-licensing of a clinical-stage program from Novartis to support the use of stem cell transplantation in a variety of disease settings; and a strategic partnership with… Read More »